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Abstract
Autophagy is the process by which cytosolic components and organelles are delivered to
the lysosome for degradation. Autophagy plays important roles in cellular homeostasis and
disease pathogenesis. Small chemical molecules that can modulate autophagy activity
may have pharmacological value for treating diseases. Using a GFP-LC3-based high con-
tent screening assay we identified a novel chemical that is able to modulate autophagy at
both initiation and degradation levels. This molecule, termed as Autophagy Modulator with
Dual Effect-1 (AMDE-1), triggered autophagy in an Atg5-dependent manner, recruiting
Atg16 to the pre-autophagosomal site and causing LC3 lipidation. AMDE-1 induced autop-
hagy through the activation of AMPK, which inactivated mTORC1 and activated ULK1.
AMDE-1did not affect MAP kinase, JNK or oxidative stress signaling for autophagy induc-
tion. Surprisingly, treatment with AMDE-1 resulted in impairment in autophagic flux and inhi-
bition of long-lived protein degradation. This inhibition was correlated with a reduction in
lysosomal degradation capacity but not with autophagosome-lysosome fusion. Further
analysis indicated that AMDE-1 caused a reduction in lysosome acidity and lysosomal pro-
teolytic activity, suggesting that it suppressed general lysosome function. AMDE-1 thus
also impaired endocytosis-mediated EGF receptor degradation. The dual effects of AMDE-
1 on autophagy induction and lysosomal degradation suggested that its net effect would
likely lead to autophagic stress and lysosome dysfunction, and therefore cell death. Indeed,
AMDE-1 triggered necroptosis and was preferentially cytotoxic to cancer cells. In conclu-
sion, this study identified a new class of autophagy modulators with dual effects, which can
be explored for potential uses in cancer therapy.
Introduction
Autophagy is a universal, dynamic degradation process that takes place in all eukaryotic cells
and contributes to the turnover and rejuvenation of cellular components via the lysosome
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pathway [1]. Autophagy plays significant roles in human diseases including cancer, neurode-
generative diseases, infectious and inflammatory diseases [2]. Because of the potential im-
portance in regulating autophagy for therapeutic manipulations, there is great demand for
potent modulators of the autophagic pathway.
Recently developed screening assays for small molecule modulators of autophagy have em-
ployed a variety of readouts [3,4,5]. The most commonly used parameter is the lipidation of
LC3, a well-established autophagosome marker [6,7,8,9]. In particular, cell-based high-content
screening assays examine the translocation of GFP-LC3 from the cytosol to autophagic mem-
branes as a result of LC3 lipidation, which causes the appearance of GFP signals in punctate
structures. A number of chemicals have been found that affect the extent of LC3 lipidation as a
result of enhanced autophagy activation or decreased autophagic degradation [6,7,8,9].
Autophagy inducers are those chemicals that can activate autophagy either via suppressing
mTORC1, such as rapamycin, or via mechanisms not related to mTORC1 suppression, such as
carbamazepine (CBZ) [10,11]. Autophagy inhibitors can work by inhibiting upstream autop-
hagy machinery, such as the Class III phosphatidylinositol 3-kinase (PIK3C3) and Beclin 1.
3-methyladenine (3-MA) is a PIK3C3 inhibitor that suppresses autophagy [12], while spautin-
1 inhibits autophagy by promoting Beclin 1 degradation [13]. Lysosome inhibitors, such as
chloroquine (CQ) and bafilomycin A1 can also inhibit autophagy at the degradation stage [8].
Bafilomycin A1 may also block autophagosome-lysosome fusion [14].
Chemical modulators have been successfully used in basic research, although their use in
the clinic is just being explored [10,11]. One of the potential uses of autophagy enhancers is in
promoting autophagic degradation of misfolded or aggregated proteins, such as mutant hun-
tingtin [15] or mutant alpha1-antitrypsin [16], whereas autophagy inhibitors could be poten-
tially used in cancer therapy [17]. Autophagy is an important biological process in cancer.
Autophagy has a suppressive effect against tumorigenesis at the initiation stage but cancer cells
could utilize autophagy for cytoprotection once the tumor is established [18]. Autophagy pro-
vides a cytoprotective mechanism for cancer cells exposed to cytotoxic therapy. A combined
use of CQ with some of the routinely used chemotherapeutic agents proves to be quite valuable
in overcoming autophagy-mediated cytoprotection in cancer therapy [17,19].
In this study, we used a high-content screening assay based on GFP-LC3 translocation to
identify potential autophagy modulators. Surprisingly, among the several potential modulators
we found one chemical that possessed a dual effect on both autophagy activation and autop-
hagy-mediated degradation. This compound, named as AMDE-1 for Autophagy Modulator
with Dual Effect-1, activated autophagy by the AMPK-mTORC1-ULK1 pathway and at the
same time inhibited autophagy-mediated degradation by causing lysosome dysfunction. We
also found that AMDE-1 had potent cytotoxic effects preferentially against cancer cells, sug-
gesting its potential applications in cancer therapy.
Materials and Methods
Antibodies and chemicals
Antibodies against AMPK, phosphor-AMPK (Thr172), UKL1, phosphor-ULK1 (Ser555),
phosphor-ULK1 (Ser757), p70S6K1, phospho-p70S6K1 (Thr389), S6, phospho-S6 (Ser235/
236), 4E-BP1, phospho-4E-BP1 (Thr37/46), cathepsin D, and EGF receptor were obtained
from Cell Signaling Technology (Danvers, MA). Antibodies against SQSTM1/ p62, LC3B and
Atg16L were purchased fromMBL International (Woburn, MA). Anti-cathepsin B and GFP
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA); and anti-LAMP2
was obtained from Developmental Studies Hybridoma Bank (Iowa City, IA). Secondary anti-
bodies conjugated with Alexa Fluor-488, Cy3 or horseradish peroxidase were purchased from
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Life Technologies (Carlsbad, CA) and Jackson Immuno Research Laboratories (West Grove,
PA), respectively.
AMDE-1 (2-[5,7-bis(trifluoromethyl)[1,8]naphthyridin-2-yl]-2-(3-chlorophenyl)acetonitrile
was repurchased from Key Organics (Bedford, MA) with a purity of>90%. Ammonium chlo-
ride (AC), chloroquine (CQ), acridine orange (AO), 3-methyladenine (3-MA and human EGF
were purchased from Sigma-Aldrich (St Louis, MO). Bafilomycin A1 (Baf) and rapamycin
(Rap) were obtained from LC Laboratories (Woburn, MA). E64d and pepstatin A were obtained
from A. G. Scientific (San Diego, CA). Z-VAD-FMK and necrostatin-1 were from SelleckChem
(Houston, TX). Other reagents used were the cocktail protease/phosphatase inhibitors (Roche,
Indianapolis, IN), Lipofectamine 2000 and LysoTracker Red (LTR, Life Technologies, Carlsbad,
CA) and L-[14C]-valine (PerkinElmer, Waltham, MA).
Cell culture
Wild type and Atg5-deficient MEFs, HEK293, A549, U251, HL60, HCT116 and CCD-18Co cells
have been described before [8]. Cells were cultured at 37°C in a humidified air atmosphere with
5% (v/v) of CO2. The complete medium is DMEM (Thermo Scientific, Rockford, IL) with 10%
(v/v) of fetal bovine serum (Gibco, Grand Island, NY) and other standard supplements. EBSS
with no serum and other supplements was used as starvation medium.
High content screening assay
The high content screening assay for autophagy modulators was based on the change in
GFP-LC3 punctation. This assay was developed, optimized, and conducted at the Pittsburgh
Molecular Libraries Screening Center (PMLSC) according to universally accepted HTS guide-
lines [20]. The optimized assay used 1 μM thapsigargin as positive control, showed DMSO tol-
erance up to 1.4%, and in multi-day variability assessments returned signal-to-background
ratios and Z-factors of 10.7/0.47, 16.3/0.30, and 5.4/0.35 on days 1, 2, and 3, respectively. The
results of the screen and a detailed protocol can be found on Pubchem (BioAssay: AID 463193;
https://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=463193). Briefly, MEFs stably express-
ing GFP-LC3 were seeded in collagen-coated 384 well microplates (Falcon Biocoat) and incu-
bated overnight in 5% CO2 at 37°C. The density of the culture was 5,000 per well in 40 μL of
complete medium (DMEM with 10% FCS). The chemical library used in this screen was the
NIHMolecular Libraries Small Molecule Collection (https://mlsmr.evotec.com/MLSMR_
HomePage/index.html). The library was stored in DMSO and diluted in complete medium be-
fore transfer to the assay plates. The final concentration of compounds was 10 μM and that of
DMSO was 1%.
After incubation for 18 hours the cells were fixed with 10 μL of fixation solution (10.7%
formaldehyde and 26.7 μg/ml Hoechst 33342 in HBSS) for 30 min. Following three washes with
PBS, the plates were analyzed on the ArrayScan VTi (Thermo Fisher Cellomics) for autophago-
somal GFP-LC3 accumulation. Images were acquired in two channels (DAPI/FITC) using a 10x
objective and an Omega XF100 filter set, and were analyzed by an in-house developed imaging
algorithm based on the Cellomics Compartmental Analysis Bioapplication (S1 Fig). In brief, a
nuclear mask was generated fromHoechst-stained nuclei. An area representative of the cyto-
plasm was generated by placing a set of concentric rings around the nuclear mask. To exclude
perinuclear fluorescence artifacts, the nuclear mask was dilated by three pixels before defining
the cytoplasmic region. Autophagosomal membrane-associated GFP-LC3 was detected as fluo-
rescent punctate objects (puncta, or spots) that exceeded a threshold defined by untreated cells
and that were located exclusively in the cytoplasmic area.
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A selection threshold was then set using DMSO-treated cells to calculate the percentage of
cells positive for GFP-LC3 puncta formation. This parameter had greater discriminatory power
than the number of cells containing puncta. Based on the results from the variability assessment
studies, we scored positive agents as those that increased the percentage of GFP-LC3 puncta
positive cells with a z-score of greater than 3 (based on plate average). To triage fluorescence
and toxicity artifacts, compounds that showed overall GFP-intensity in the cytoplasm greater
than 1500 and caused more than 80% cell loss were eliminated.
Immunoassay
For immunoblot assay, proteins were separated by SDS-PAGE and transferred to PVDFmem-
branes (Millipore, Billerica, MA). Primary antibodies were used, followed by HRP-conjugated
secondary antibodies. Specific proteins were detected using Immobilon western chemilumines-
cence HRP substrate (EMDMillipore, Billerica, MA). Densitometry was performed with a Kodak
Image Station 4000 and the companion software (Carestream Health, Inc. Rochester, NY).
Immunofluorescence staining was carried out as described previously [8]. Briefly, cells were
grown on glass cover slips and were fixed in 4% formaldehyde followed by permeabilization
and blocking in PBS containing 2% bovine serum albumin (BSA). Primary and Alexa488-con-
jugated secondary antibodies were applied sequentially. Samples were mounted on glass slides
after nuclei staining. Fluorescence images were taken using a Nikon Eclipse TE200 Epi-fluores-
cence microscope with NIS-Elements AR3.2 software. At least 50 cells per experimental condi-
tion were analyzed for quantification.
Long-lived protein degradation assay
Long-lived protein degradation assay was performed as previously described [21]. Briefly, cells
were cultured in DMEM in 24-well plates. L-[14C]-valine was added to a final concentration of
0.2 μCi/ml to label intracellular proteins. Cells were seeded for 18 h before changing to fresh
medium with 10% cold L-valine for another hour to deplete labeled short-lived proteins. The
cells were then incubated in EBSS or DMEM (plus 0.1% of BSA and 10 mM valine) with or
without the testing chemicals for an additional 6 or 16 hours. The culture medium was then re-
covered, from which the degraded long-lived proteins were measured via liquid scintillation
(Beckman LS 6000).
Analysis of lysosome function
Lysosomal acidity was examined by incubating cells with LTR (50 nM) or AO (1 μg/ml) for 20
to 30 minutes at 37°C in complete medium followed by treatment. The fluorescence intensity
was then measured by fluorescence microscopy.
The enzymatic activity of cathepsins was measured as previously described [8]. Briefly,
after experimental treatment cells were suspended in hypotonic buffer (40 mM KCl, 5 mM
MgCl2, 2 mM EGTA, 10 mM HEPES, pH 7.5) for 30 min on ice. Cells were homogenized by
shearing through a 28.5 G needle for 30 times and the lysosome-enriched fraction (P10) was
isolated by differential centrifugation, which was washed in an isotonic buffer (150 mM NaCl,
5 mMMgCl2, 2 mM EGTA, 10 mMHEPES, pH 7.5) and dissolved in native lysis buffer (1%
Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, pH 7.5) for activity analysis. The substrates
Z-FR-AMC and Mca-Gly-Lys-Pro-Ile-Leu-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 (Enzo Life
Sciences, Farmingdale, NY) was used for cathepsin B and cathepsin D assay, respectively.
To determine the lysosomal degradation capacity, cells were incubated with 10 μg/ml of
self-quenched bodipy-conjugated BSA (DQ-BSA Red) for 1 h at 37°C. Following the wash new
medium was added with or without the designated chemicals for 4 to 6 h. Degradation capacity
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was measured by monitoring the appearance of red fluorescent dots due to the degradation of
DQ-BSA-Red, which was then quantified.
Analysis of EGF receptor degradation
HeLa cells were starved in serum-free medium DMEM for 1.5 h and were either mock-treated
as controls or incubated with EGF (200 ng/ml) with cycloheximide (20 μg/ml) and other desig-
nated chemicals in 37°C for 0–4.5 hours. Cells were then washed with cold PBS and immediate-
ly lysed. Lysates were analyzed by immunoblotting assay using an anti-EGF receptor antibody.
Cell viability assay
Cells were seeded at 5×103 per well in 96-well plates and incubated overnight with the designat-
ed chemicals for 24–48 h. Cell viability was measured by adding 10%MTS (CellTiter 96, Pro-
mega Corporation, Madison, USA) for additional 2 h. The absorbance was measured at 490
nm with a spectrophotometer (Infinite M1000, Tecan). Cell death was calculated from three in-
dependent experiments and normalized to the absorbance of wells containing medium only
with no cells (100%) and that of wells containing untreated cells (0%). Dose responses were fit-
ted with appropriate regression models using Microsoft Excel’s Trendline tool. EC50 doses
were calculated using the regression equations, where the 50% response point was defined
using the full range of response (0–100%) for the absolute EC50 values and using the detected
response range (analyte-specific) for the relative EC50 values.
Statistical analysis
All data are presented as the mean ± SD from at least three separate experiments. The p values
were determined by two-tailed Student’s t-test. P< 0.05 was considered as being significant.
Results
High Throughput screening for modulators of GFP-LC3 punctation
Using murine embryonic fibroblasts (MEFs) that express GFP-LC3 we conducted a high con-
tent screening for potential chemical modulators of autophagy based on changes in GFP-LC3
translocation to autophagosomal membranes (S1 Fig). A total of 1,963 chemicals from the li-
brary of 196,160 compounds were found to be positive for upregulating GFP-LC3 puncta
based on the criteria described in the Methods section. This yielded a hit rate of 1%. The results
of this screen, including experimental details, have been deposited to PubChem (AID: 463193).
One thousand seven hundred thirty (1730) compounds were available for cherry-picking and
were retested at the single-dose of 10 μMusing the same image analysis algorithm used in the
primary screen. Seven hundred twenty one (721) agents increased the number of cells with
puncta by more than three standard deviations over the negative control (confirmation rate:
42%), and were subjected to three independent ten-point dose dependence trials (20 nM to
10 μM). Average EC50s were calculated from all three experiments; EC50 values that were arti-
facts of curve fitting were eliminated. The remaining compounds were visually examined for the
presence of puncta at 10 μM. Compounds were eliminated if there was a presence of fluorescent
artifacts, if the compound precipitated out of solution, or if the compound did not demonstrate a
clear punctate phenotype. Fifty six agents had complete dose responses with EC50 values below
10 μM (S1 Table). Structural similarity analysis using Leadscope Enterprise 2.4.6–1 Chemical
Structure analysis software revealed nine clusters for 24 agents and 32 singletons. All 56 agents
were subsequently re-examined in MEFs stably expressing GFP-LC3 and their ability to induce
GFP-LC3 puncta was quantified manually. This allowed a rigorous visual confirmation and the
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percentage of cells with 5 or spots per cells were calculated (S2 Table). Furthermore, the specifici-
ty of their effects was evaluated using MEFs lacking Atg5, an essential gene for autophagy. Final-
ly, we usedWestern blot analysis to examine the lipidated form of GFP-LC3 as an alternative
way to confirm the effects of the top hits (S2 Table). The multiple secondary assays ensured that
the effect of these chemical compounds in modulating GFP-LC3 puncta was authentic and re-
peatable. Several of these compounds were found to be non-specific (e.g., SID 14741249, SID
17408254 and SID 14733320) or to cause cellular destruction (e.g.,SID 14729169, SID17507447
and SID 24826599).
AMDE-1 is a novel compound that can activate autophagy
Several agents caused rapid and sustained accumulation of autophagosomes in GFP-LC3-MEFs.
One of them was brefeldin A (SID 855810), which is a known autophagy inducer [22], thus
validating the screen and the secondary assay scheme. The most potent and specific inducer of
autophagy was SID 14730495, which caused 96.7% of cells to accumulate GFP-LC3 puncta at
the earliest time point (11 hours) and had essentially no activity in Atg5KO-MEF (S2 Table).
We thus decided to conduct an in-depth analysis for the mechanism by which it affected autop-
hagy. This compound, which we named Autophagy Modulator with Dual Effect-1 (AMDE-1),
has a molecular weight of 415.7 (C18H8ClF6N3) (Fig 1A) and its chemical name based on IUPAC
Fig 1. AMDE-1 can induce autophagy. (A) The molecular structure of AMDE-1. (B-C) A549, wild type MEFs and Atg5 KOMEFs expressing GFP-LC3 were
treated with or without AMDE-1 (10 μM) for 6 h, and then analyzed by GFP-LC3 puncta formation (B) or by immunoblotting (C). (D-E) A549, wild type MEFs
and Atg5 KOMEFs were treated with 1 μM rapamycin (Rap) or 10 μMAMDE-1 for 6 h, followed by immunostaining with an anti-Atg16L1 antibody (D).
Atg16L1 puncta were quantified (E). Values represent means ± SD from three independent experiments. ***: p<0.001. CM: control medium.
doi:10.1371/journal.pone.0122083.g001
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(International Union of Pure and Applied Chemistry) nomenclature is 2-[5,7-bis(trifluoro-
methyl)[1,8]naphthyridin-2-yl]-2-(3-chlorophenyl)acetonitrile.
As found in our screening assay, AMDE-1 induced GFP-LC3 puncta in the MEFs. This in-
duction was specific to autophagy activation as it was eliminated in cells lacking Atg5, a key
autophagy gene (Fig 1B, S2 Table). GFP-LC3 puncta could also be observed in other types of
cells such as A549 (Fig 1B, S2 Table, Saos2 (S2 Table), and HEK293 (Fig 2). Consistent with
the imaging analysis, lipidation of GFP-LC3 (S2 Table) and of endogenous LC3 was detected
by immunoblotting in wild type but not in Atg5-deficient MEFs (Fig 1C). During autophagy
initiation, Atg5 is conjugated with Atg12, which is bound to Atg16L1 to form a complex on
the pre-autophagosomal membrane that is necessary for the lipidation of LC3 and autophago-
some formation [23,24]. Atg5-Atg12-Atg16L1 complex is then detached from the completed
Fig 2. AMDE-1 can induce autophagy through AMPK-mTOR-ULK1 pathway. (A) Wild-type MEFs and HeLa cells were treated with or without 10 μM of
AMDE-1 for 6 h. Phosphorylation of S6 was detected by immunoblotting assay. (B-C) MEFs were treated with 10 μMAMDE-1 (B), or chloroquine (CQ,
40 μM) or E/P (E64D, 25 μM plus pepstatin A, 50 μM) (C) for different times as indicated and analyzed byWestern blot. The zero time point represents no
treatment. (D-E) MEFs expressing GFP-LC3 were treated with AMDE-1 alone or together with N-acetyl cysteine (NAC, 20 μM), U0126 (30 μM), or SP600125
(20 μM) for 6 h. GFP-LC3 puncta formation (D) and endogenous LC3 level were analyzed (E).
doi:10.1371/journal.pone.0122083.g002
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LC3-positive autophagosomes, therefore acting as an early autophagy marker independent
of later events like fusion with, and degradation in, the lysosome. When stained with an anti-
Atg16L1 antibody, both A549 and MEFs treated with AMDE-1 demonstrated the formation of
Atg16L1-positive puncta in a pattern (Fig 1D) and at the level (Fig 1E) comparable to that in-
duced by a classic autophagy inducer, rapamycin (Rap). Furthermore Atg16L1 punctation, like
LC3 punctation, depends on Atg5. Taken together, these data strongly indicated that AMDE-1
was able to initiate autophagy using the defined autophagy machinery.
The AMPK-mTOR-ULK1 pathway is involved in AMDE-1 induced
autophagy
Small molecules can affect autophagy activation through either mTOR-dependent or mTOR-in-
dependent pathway [11]. We examined whether AMDE-1 initiated autophagy by affecting
mTOR signaling. Indeed, we found that AMDE-1 suppressed the phosphorylation of S6, a
downstream target of mTORC1, in both MEFs and HeLa (Fig 2A). A time-dependent analysis
in MEFs indicated that the effect could be detected 1 hour after treatment and was associated
with the inhibition of p70S6 kinase and 4E-BP1, both being direct targets of mTORC1 (Fig 2B).
AMPK can promote autophagy indirectly by inactivating mTORC1 and directly by activating
the ULK1/Atg1 complex [25,26]. We found that in the same time frame as mTORC1 was inhib-
ited phosphorylation of AMPK at Thr172 was increased, indicating that AMDE-1 could inhibit
mTORC1 by activating AMPK.
As AMDE-1 had also inhibitory effects on the lysosome (see below), we wondered whether
AMPK activation could be triggered by a general suppression of the lysosome function. Treat-
ment of cells with chloroquine, which reduced lysosomal acidity, or with E64D plus pepstatin
A, which inhibited the lysosomal proteases, did not lead to AMPK phosphorylation, despite
that these chemicals inhibited S6 phosphorylation as reported before [8] (Fig 2C). These results
indicate that lysosomal suppression does not necessarily lead to AMPK activation, and that
AMDE-1 can activate AMPK, and thus autophagy, independently of lysosome inhibition.
Canonical autophagy is initiated at the ULK1/Atg1 complex, which is evolutionarily con-
served from yeast to the mammals [2]. Mammalian ULK1 is inhibited by mTORC1 through
the phosphorylation at Ser757 whereas it can be activated by AMPK through the phosphoryla-
tion at Ser555 [25,26]. Indeed, we found that AMDE-1 treatment caused an increased ULK1
phosphorylation at Ser555 but a decreased phosphorylation at Ser757 in a time-dependent fash-
ion (Fig 2B), supporting the roles of an activated AMPK and an inactivated mTOC1 in
AMDE-1-stimulated autophagy activation.
Several other signaling pathways including ERK, JNK and reactive oxygen species (ROS)
have been reported to be involved in autophagy activation [27,28]. However, by employing
U0126, SP600125 or N-acetyl cysteine (NAC) to respectively suppress these signaling modali-
ties, we did not observe any changes in GFP-LC3 punctation (Fig 2D) or LC3 lipidation (Fig
2E) induced by AMDE-1, suggesting that they were not critically involved in AMDE-1-induced
autophagy. Taken together, these findings indicate that AMDE-1 induced autophagy by acti-
vating AMPK and inactivating mTORC1.
AMDE-1 can inhibit autophagic degradation
Despite the induction of autophagy by AMDE-1 we noticed that AMDE-1 caused an arrest of
autophagy flux. The level of LC3-II in cells treated with AMDE-1 plus chloroquine (CQ) was no
higher than that of cells treated with AMDE-1 alone after 20 hours in culture (Fig 3A and 3B).
The difference between the two conditions would represent the amount of LC3-positive autop-
hagosomes being degraded through the lysosome. Thus the results suggested that AMDE-1
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treatment did not result in autophagic flux. Consistent with this notion, the level of SQSTM1/
p62, a sensitive autophagic substrate, increased over time in the presence of AMDE-1 (Fig 3C
and 3D). Interestingly, the accumulation of p62 could be detected at 6 hours after treatment,
suggesting that the interference could occur early on.
To assess autophagy flux at an early time, we measured the fluorescence change of a tan-
dem RFP-GFP-LC3 construct, which offered a more sensitive and dynamic assay [29]. The
normal autophagy process will lead to quenching of GFP once the autophagosome carrying
RFP-GFP-LC3 reaches the acidic environment of the lysosome, but the red fluorescence of
RFP will not be affected. Thus if the autophagosome is degraded in the lysosome, only red
fluorescence will be detected. In contrast, if the autophagosome is not degraded in the lyso-
some, both RFP and GFP will remain, giving rise to a yellow fluorescence. As anticipated, in
HEK293 cells expressing this construct treatment with rapamycin resulted in an increase of
total puncta as well as the red fluorescence puncta (Fig 3E and 3F), indicating autophagy acti-
vation and the degradation of the labeled autophagosome. In contrast, CQ treatment resulted
in increased yellow puncta but decreased red-only puncta, consistent with its effect to inhibit
Fig 3. AMDE-1 can inhibit autophagic degradation. (A-B) MEFs were treated with or without AMDE-1 (10 μM) and CQ (40 μM) for 20 h. Endogenous LC3
was analyzed by immunoblot assay (A) and densitometry (B). (C-D) MEFs were treated with AMDE-1 (10 μM) for 0–20 h as indicated. The level of SQSTM1/
p62 was analyzed (C) and quantified (D). (E-F) HEK-293A cells expressing GFP-RFP-LC3 were treated with CQ (40 μM), Rap (1 μM) and AMDE-1 (10 μM)
for 6 h (E). Puncta showing both green and red fluorescence (indicated as yellow), or showing only the red fluorescence (indicated as red) were quantified
(F). (G-H) MEFs were incubated in complete medium (CM), or in EBSS with or without AMDE-1 (10 μM), 3-MA (10 mM), CQ (10 μM), Rap (1 μM) or CBZ
(50 μM) for 6 h (G) or 16 h (H). The long-lived protein degradation was measured. For panel B, D, F, G and H, values represent means ± SD from three
independent experiments. ***: p<0.001; **: p<0.01.
doi:10.1371/journal.pone.0122083.g003
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the lysosome (Fig 3E and 3F). The AMDE-1 treatment for 6 hours presented a pattern similar
to that of CQ treatment, suggesting a reduced degradation of autophagosomes.
To determine the functional impact of AMDE-1 on autophagy flux, we examined the long-
lived protein degradation, which is considered to be the gold standard for assessing autophagy
function [30]. Cells incubated in the starvation medium (EBSS) for 6 hours increased long-
lived protein degradation, which was inhibited by 3-methyl adenine (3-MA) and CQ, which in-
hibit autophagy at the initiation and degradation stage, respectively (Fig 3G). The autophagy
stimulator, carbamazepine (CBZ), could slightly further increase EBSS-induced long-lived pro-
tein degradation. However, AMDE-1 suppressed the degradation as CQ did. Furthermore,
AMDE-1 inhibited long-lived protein degradation induced by rapamycin or CBZ in a 16-hour
culture (Fig 3H). These data indicated that AMDE-1 plays a dual role in regulating autophagy
by initiating autophagy but also by blocking autophagic degradation.
AMDE-1 can suppress lysosomal degradation
To elucidate how AMDE-1 might inhibit autophagy degradation we first examined the coloca-
lization of AMDE-1-induced GFP-LC3 puncta with the lysosomes as detected by the anti-
LAMP2 antibody (Fig 4A). We observed a significant level of colocalization between the two
signals, implying that AMDE-1 did not block the fusion between the autophagosome and the
lysosome. We then assessed whether AMDE-1 could affect the lysosome acidity. We used two
sensitive pH probes that can accumulate in the lysosome. AO is a lysosomotropic metachro-
matic fluorochrome, and presents green fluorescence in the cytosol but red fluorescence when
it is accumulated in the acidic compartment due to its being highly protonated [31]. Lyso-
Tracker Red (LTR) manifests red fluorescence in a pH-dependent manner in the lysosome. As
seen in Fig 4B, while ammonium chloride (AC) neutralized the pH of the lysosome, resulting
in the disappearance of the red fluorescence of both AO and LTR, AMDE-1 had no effect on
the fluorescence intensity of the two probes. Thus AMDE-1 did not seem to affect the acidity
of the lysosome.
However, we did find that AMDE-1 inhibited lysosome-specific degradation with the
DQ-BSA assay. When DQ-BSA is degraded under normal lysosomal conditions, it releases red
fluorescence in the lysosome. Treatment of AMDE-1, as well as CQ and E64d plus pepstatin A,
caused a significant reduction of DQ-BSA-related red fluorescence (Fig 4C). This result sug-
gested that AMDE-1 might have a general inhibitory effect on the lysosome’s degradation ca-
pacity, not just limited to autophagic degradation. To examine this possibility, we examined
whether AMDE-1 could affect the degradation of EGF receptor (EGFR) in the lysosome. EGFR
was endocytosed upon the addition of EGF to the cell. The degradation of EGFR was moni-
tored by immunoblotting at different times after the addition of EGF (Fig 4D). Degradation of
EGFR in normal condition was apparent at 2 hours after EGF addition. AMDE-1, like bafilo-
mycin A1 (Baf), a classical lysosome inhibitor, was able to inhibit EGFR degradation in
this assay.
To examine how AMDE-1 might affect the lysosomal degradation we isolated the lysosome
fraction from AMDE-1-treated cells by differential centrifugation. While the protein level of
cathepsin D (CTSD) had not changed, the level of matured cathepsin B (CTSB) was decreased
(Fig 4E). Consistently, the enzymatic activity of CTSB was significantly reduced while that of
CTSD only decreased slightly (Fig 4F). Taken together, these results indicated that AMDE-1
could inhibit the function of the lysosome by affecting the maturation and activity of selected
proteases. This effect led to the inhibition of both autophagic and non-autophagic degradation
in the lysosome.
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Fig 4. AMDE-1 can block lysosome degradation. (A) GFP-LC3-expressing MEFs were treated with AMDE-1 (10 μM) for 6 h, followed by immunostaining
with anti-LAMP2. Arrows indicated colocalized GFP-LC3 (green) and LAMP2 (red) puncta. (B) HeLa cells were treated with AMDE-1 (10 μM) for 6 or 20 h or
with ammonium chloride (AC, 20 mM) for 2 hr. as indicated, followed by staining with acridine orange (AO, 1 μg/ml) or Lyso Tracker Red (LTR, 50 ng/ml) for
30 min. (C) HeLa cells were pre-incubated with self-quenched bodipy-conjugated BSA (DQ-BSA, 10 μg/ml) for 1 h and then treated with AMDE-1 (10 μM),
E64D (25 μM) plus pepstatin A (50 μM) (E+P) or CQ (40 μM) for 6 h. (D) HeLa cells were starved in DMEM for 1.5 h and incubated with or without EGF (200
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AMDE-1 is a potent cytotoxic agent for cancer cells
Since AMDE-1 modulated autophagy at both the induction and degradation phase and it af-
fected the lysosome function significantly we hypothesized that AMDE-1 could be explored as
a chemotherapeutic agent for cancer therapy. In many cases, it has been shown that the toxicity
of a chemotherapeutic agent could be enhanced by CQ since cancer cells can often mount a
protective autophagy response toward the chemotherapeutic agent [17]. Being a dual modula-
tion agent, AMDE-1 alone may serve this purpose. Indeed, AMDE-1 induced a dose-depen-
dent cell death in HeLa cells in 48 hours (Fig 5A). The relative EC50 was calculated to be
1.1 μM. In contrast, the relative EC50 of CQ in the same type of cells was 27.5 μM, or about
25-fold higher (Fig 5B). Thus the toxicity of CQ at a low dose would become obvious only
when in combination with other chemotherapeutic agents [19], whereas AMDE-1 at the same
low dose seemed to be sufficient to cause significant cell death by itself. We compared the toxic-
ity of the two agents in a number of other cancer cell lines, including a glioma cell line, U251; a
colon cancer cell line, HCT116 and an erythroleukemia cell line K562 (Fig 5C). In each of these
cases, 2.5 μM of AMDE-1 caused the same level of cell death as 50 μM of CQ, confirming that
AMDE-1 was much more potent than CQ. Interestingly both agents could kill Atg5-deficient
MEFs, though at a relatively lower rate, compared to the rate for some of the cancer cells. This
result indicated that CQ and AMDE-1’s toxicity could be mediated by the lysosome-toxic effect
without involving autophagy activation.
Both CQ and AMDE-1 can be toxic to non-transformed immortalized cells, such as MEFs
and CCD-18Co cells, which are colonic cells (Fig 5C). It is worth to note that at the same effec-
tive doses AMDE-1 was less toxic than CQ to the non-transformed CCD-18Co cells and wild
type MEFs, suggesting that AMDE-1 might have a better selectivity toward cancer cells. To fur-
ther investigate this possibility, we compared the dose responses of HCT116 colon cancer cells
and CCD-18Co cells to AMDE-1. Indeed, AMDE-1 induced a higher level of cytotoxicity in
HCT116 cells than in CCD-18Co cells (Fig 5D). While the relative EC50 of AMDE-1 for
HCT116 was 1.3 μm, that for CCD18-Co cells was 2.6 μm, or one-fold higher. When the dose
response was normalized for the maximal response (100%), the absolute EC50 of AMDE-1 in
HCT116 was 1.9 μm and that in CCD18-Co cells was 12.8 μm, or about 5.7-fold higher. Thus
AMDE-1 seemed to be more selectively toxic to the transformed tumor cells.
To determine the mode of cell death induced by AMDE-1we added z-VAD-fmk, a pan-
caspase inhibitor, or necrostatin-1, a RIP1 kinase inhibitor, to AMDE-1-treated cells. Necrosta-
tin-1, but not z-VAD-fmk, was able to block AMDE-1 induced cell death in HCT116 cells (Fig
5E), suggesting that AMDE-1 induced necroptosis, but not apoptosis. Taken together, these re-
sults indicated that AMDE-1 could be explored as a cancer therapeutic agent with a potentially
wide therapeutic window.
Discussion
The discovery of useful small molecule modulators for autophagy is still challenging due to
the complexity of the autophagic process. Several types of screening assays have been estab-
lished that are based on a number of different parameters. Although by far the largest
number of assays have used LC3 lipidation as the readout [6,7,8,9], assays based on PtdIns(3)P
ng/ml) together with Baf (0.5 μM) or AMDE-1 (10 μM) for 0–4.5 h. EGFR level was detected by immunoblot. (E) Hela cells were treated with AMDE-1 (10 μM)
for 0–20 h. The lysosome-enriched fraction was analyzed for the expression of cathepsin D (CTSD) and cathepsin B (CTSB). (F) Cells were treated with or
without AMDE-1 for 20 hrs, and the activity of cathepsin B and cathepsin D at 20 h was analyzed using the lysosome-enriched fraction. Cathepsin activities
were standardized to that of the untreated sample, which was set to 100%. Values represent means ± SD from three independent experiments. ***:
p<0.001.
doi:10.1371/journal.pone.0122083.g004
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accumulation [6,7,8,9], Atg4 cleavage activity [3,5], and lysosome degradation [32] have also
been developed. In addition, a functional screening was also successful in identifying chemicals
that affect lipophagy [4]. The diversity of the screening platforms leads to the discovery of
many different chemicals that can directly or indirectly affect the readout and therefore autop-
hagy function. It is thus important to carefully dissect the potential mechanisms involved in
each of these compounds to determine whether they can serve as chemical probes in research
or have the potential for future therapeutic applications.
AMDE-1 is a unique autophagy modulator that emanated from a high throughput screen of
196,160 compounds for LC3-GFP accumulation in punctate structures. Chemicals can affect
GFL-LC3 distribution in a number of ways. After excluding non-specific effects, the increase or
decrease in GFP-LC3 puncta could be attributed to either changes in autophagy activation or
changes in autophagic degradation. Thus positives from the screen could be either autophagy
inducers or inhibitors. Using a series of detailed mechanistic studies, we found that AMDE-1
represents a mechanistically unique compound that can exert both effects, but at different
stages. Acting as an autophagy activator at the initiation stage and an autophagy inhibitor at
Fig 5. AMDE-1 is a potent cytotoxic agent. (A-B) HeLa cells were treated with AMDE (A) or CQ (B) at different doses for 48 hours. Cell death was
measured. The dose responses were fitted with a logarithmic regression (A) or a second order polynomial regression (B) algorithm, respectively. (C) Cells
were treated with CQ (50 μM) or AMDE (2.5 μM) for 48 hours. Cell death was then measured. (D) HCT116 and CCD-18Co cells were treated with AMDE at
different concentrations for 48 hours. Cell death was measured. The dose response was fitted with a logarithmic regression algorithm. (E) HCT16 was treated
with or without AMDE-1 (2.5 μM), zVAD (20 μM), and/or necrostatin-1 (necro, 40 μM) for 48 hours. Cell death was measured. Values represent means ± SD
from three independent experiments. *: p<0.05, ***: p = 0.001.
doi:10.1371/journal.pone.0122083.g005
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the degradation stage causes a significant increase in GFP-LC3 puncta due to the failure to de-
grade the accumulated autophagosomes (Fig 6).
mTORC1 is one of the key suppressor of autophagy, which is positively regulated by up-
stream signals such as growth factors and amino acids, but negatively regulated by AMPK [33].
mTORC1 and AMPK can phosphorylate ULK1 at different sites, leading to its inactivation or
activation respectively [25,26]. AMDE-1 induced canonical autophagy in Atg5 and Atg16L de-
pendent fashion. Furthermore, it activated AMPK and suppressed mTORC1, which affected
the phosphorylation pattern of ULK1, leading to its activation to promote autophagy.
The inhibitory effect of AMDE-1 on autophagy degradation was demonstrated by the
accumulation of p62/SQSTM1, long-lived proteins and autophagosomes (as measured by the
Fig 6. A proposedmode for the action of AMDE-1. AMDE-1 can trigger autophagy by the AMPK-
mTOR-ULK1 pathway. However, AMDE-1 can also suppress lysosomal function and thus autophagic flux.
Consequently, the lysosome dysfunction and/or the accumulation of non-degraded cellular material can
promote cell death. The dashed arrow suggests that AMDE-1 may also affect autophagy by other
unknownmechanisms.
doi:10.1371/journal.pone.0122083.g006
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tandem GFP-RFP construct), which is likely due to suppression of lysosome enzyme matura-
tion and activity. On the other hand, it does not seem that AMDE-1 is able to alter the lyso-
some acidity. Several well-established lysosome inhibitors including CQ, BafA1 and AC act to
reduce lysosome acidity. Chemicals such as E64D and pepstatin can inhibit lysosome activity
and AMDE-1 seems to work in a similar way. Although we have demonstrated that AMDE-1
could suppress the activity of cathepsin B, but not cathepsin D, using the lysosomal fraction,
we had not tested this effect using recombinant enzymes. In addition, the substrates used for
assessing cathepsin B and D activity could be also hydrolyzed by cathepsin C, L, and E, respec-
tively. So it is necessary in future studies to use a panel of purified recombinant cathepsins to
examine whether they could be directly affected by AMDE-1. It is also possible that lysosome
enzymes other than proteases could be affected by AMDE-1. Nevertheless the present study es-
tablishes that AMDE-1 inhibits lysosomal function by affecting the activity of lysosome en-
zymes, but not lysosomal acidity.
The suppression of lysosome function could have an unexpected effect on autophagy activa-
tion because a normal lysosome function is also required for mTORC1 activation [8,34]. We
had found previously that prolonged lysosome inhibition will lead to down-regulation of
mTORC1 and thus in turn activation of autophagy [8]. We cannot rule out that AMDE-1
could inhibit mTORC1 in this fashion, particularly at the later stage. However, AMDE-1 can
inhibit mTORC1, independently of lysosome inhibition, via AMPK activation at an early time
point. Lysosome inhibition by CQ, E64D and pepstatin A do not activate AMPK, indicating
that the ability of AMDE-1 to activate AMPK is unique and is not dependent on lysosome sup-
pression. AMPK can also activate ULK1 at Ser555 independently of mTORC1, and thus would
be also independent of lysosome inhibition. Taken together, AMDE-1 can induce autophagy
via early upstream signaling events, other than the possible later feedback from the lysosome
inhibition. Certainly, we could not rule out that AMDE-1 could affect autophagy by additional
unknown mechanisms.
Small molecules that can induce and inhibit autophagy have received considerable attention
as they can be useful pharmacological probes to dissect the complex autophagy process and
may be explored as potential therapeutic agents. Autophagy inducers such as rapamycin and
CBZ have been used to alleviate the pathology of neurodegeneration [15] and alpha-1 anti-
trypsin deficiency [16] in animal models. A clinical trial has recently been launched for the lat-
ter (NCT01379469). One of the major possible applications of autophagy inhibitors could be
for cancer therapy. Being under increased metabolic pressure, cancer cells may be more suscep-
tible to the suppression of autophagy than non-cancerous cells [35]. Many studies have shown
an increased effectiveness in controlling cancer cell growth when autophagy inhibitors are used
in combination with standard chemotherapy or radiation therapy [17]. Several clinical trials
have already been launched [17] and the preliminary results seem to be promising [36]. Inhibi-
tors of autophagy degradation that are most commonly used in these studies are chloroquine
(used in research) or its derivative hydroxychloroquine (used in human trials) because it is an
FDA-approved drug in clinical use.
It is reasonable to assume that compounds that enhance autophagy induction while simulta-
neously impairing lysosomal degradation function could be quite useful as standalone agents for
cancer therapy (Fig 6). Such agents can be cytotoxic because they are able to cause accumulation
of more autophagosomes that fail to be degraded. Indeed AMDE-1 alone is sufficient to cause
significant cell death at a dose that would not be toxic for CQ. CQ would need an about 24 times
more dose to be equivalently toxic. The toxicity is also in part relevant to the dysfunction of lyso-
some that affects other non-autophagy functions, such as endocytosis. This may explain that
AMDE-1 is still toxic to Atg5-deficient MEFs where autophagy level would be minimal. Never-
theless, lysosome dysfunction in the presence of autophagy can be highly detrimental [37]. We
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noticed that AMDE-1 was less toxic to non-transformed cells, such as MEFs and a colon cell
line, CCD-18Co, which is a desired feature of antineoplastic agents and may translate into thera-
peutic benefit. It is important to further test AMDE-1 in animal models for its potential use in
cancer therapy.
In summary, we have identified a molecule that could represent a new genre of autophagy
modulators with dual effects in autophagy initiation and degradation. This novel property may
be explored for selective killing of cancer cells that have a higher demand on autophagy function.
Supporting Information
S1 Fig. Imaging algorithm for the quantification of GFP-LC3-positive autophagosomes.
Mouse embryonic fibroblasts (MEFs) stably expressing GFP-LC3 (5,000/well) were cultured
with thapsigargin (TG, 0.25 uM) for 18 hours. Accumulation of GFP-LC3 in autophagosomal
membranes (bright spots) was induced. Cells were imaged on an Array Scan II using a 20X ob-
jective and an Omega XF100 dual-bandpass filter set at excitation/emission wavelengths of
350nm/461nm (Hoechst) and 484nm/515nm (GFP), respectively. Cells were identified by
Hoechst 33342 staining and compartmentalized into nuclear (blue outline) and cytoplasmic
(green outlines) areas. The algorithm was interactively modified to quantify vesicular objects
located in the cytoplasm (traced in yellow).
(PDF)
S1 Table. The fifty-six top hits from the high content screening for chemical modulators of
GFP-LC3 punctation.
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